Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.
Type:
Grant
Filed:
January 24, 2019
Date of Patent:
November 23, 2021
Assignee:
THE INVENTION SCIENCE FUND II, LLC
Inventors:
Roderick A. Hyde, Wayne R. Kindsvogel, Gary L. McKnight
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Abstract: In some aspects, the invention relates to compositions comprising marrow infiltrating lymphocytes (“MILs”). The MILs may be activated MILs. In some aspects, the invention relates to methods for activating MILs, comprising incubating MILs in an environment comprising less than 21% oxygen. In some aspects, the invention relates to methods for treating cancer in a subject, comprising administering to the subject a composition comprising activated MILs.
Abstract: The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy.
Type:
Grant
Filed:
January 6, 2020
Date of Patent:
November 2, 2021
Assignees:
BIONTECH US INC., Stichting Het Nederlands Kanker Instituut—Antoni Van Leeuwenhoek Ziekenhuis
Inventors:
Marit M. Van Buuren, Divya Reddy Lenkala, Joost Huibert Van Den Berg, Jessica Kohler, Matthew Goldstein, Ed Fritsch, Renate De Boer, Ton Schumacher, Noor Bakker
Abstract: Methods and composition for production of T cells are provided. Also provided are therapeutic methods using engineered T cells. For example, in certain aspects methods include preparing three dimensional cell culture compositions comprising stroma cells and hematopoietic stem or progenitor cells in a serum-free medium for producing T cells.
Type:
Grant
Filed:
October 28, 2016
Date of Patent:
October 26, 2021
Assignee:
The Regents of the University of California
Inventors:
Gay M. Crooks, Amélie Montel-Hagen, Christopher Seet
Abstract: The present disclosure relates to a novel process for expanding T cells, such as autologous T cells, cell populations therefrom, pharmaceutical compositions comprising the said cell populations and use of the cells and compositions for treatment, particular the treatment or prophylaxis of virus infection and/or cancer, for example in immune compromised or immune competent human patients.
Type:
Grant
Filed:
August 29, 2018
Date of Patent:
October 26, 2021
Assignees:
Baylor College of Medicine, Cell Medica Inc.
Abstract: Methods of modulating high mannose glycoform content of a protein in a cell culture by contacting the cells expressing the protein of interest with monesin are provided.
Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
Type:
Grant
Filed:
March 4, 2019
Date of Patent:
September 28, 2021
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: This disclosure relates to methods of culturing and characterizing antibody secreting cells. In certain embodiments, this disclosure relates to methods of isolating antibody secreting cells, e.g., long lived plasma cells, replicating the isolated cells in growth media disclosed herein, and determining the nucleic acids sequences in the cells that encode the produced antibodies.
Type:
Grant
Filed:
May 30, 2018
Date of Patent:
September 21, 2021
Assignee:
Emory University
Inventors:
Frances Eun-Hyung Lee, Ignacio Sanz, Doan C. Nguyen
Abstract: This disclosure relates to growth media and environments for in vitro culturing of cells that produce or are capable of producing antibodies. In certain embodiments, the media comprises IL-6, fibronectin, and typically a saccharide. In certain embodiments, the disclosure contemplates cell culture compositions comprising IL-6 and fibronectin that are derived from proteins secreted from mesenchymal stromal/stem cells (MSCs). In certain embodiments, the disclosure contemplates enclosures comprising culture compositions disclosed herein that are in ambient air or optionally in an environment wherein oxygen is absent or at a low concentration.
Type:
Grant
Filed:
June 9, 2016
Date of Patent:
September 21, 2021
Inventors:
Frances Eun-Hyung Lee, Ignacio Sanz, Doan Nguyen
Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
Type:
Grant
Filed:
March 11, 2021
Date of Patent:
September 21, 2021
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: The present invention refers to a method of producing immunosuppressive bleed cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease.
Type:
Grant
Filed:
May 19, 2017
Date of Patent:
September 21, 2021
Assignee:
Universitatsklinikum Heidelberg
Inventors:
Peter Terness, Gerhard Opelz, Helmut Simon, Sandra Ehser, Christian Kleist, Flavius Sandra-Petrescu, Mircea Iancu, Lucian Jiga, Jing-Jing Chuang, Thilo Oelert
Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
Type:
Grant
Filed:
March 4, 2019
Date of Patent:
September 14, 2021
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: Provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating naïve T cells from a mammal, wherein the mammal is not a mouse; b) activating the naïve T cells and expanding the numbers of naïve T cells in the presence of one or more non-specific T cell stimuli, one or more cytokines, and a GSK-3beta inhibitor. Also provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating lymphocytes from a mammal; b) sorting the lymphocytes using flow cytometry into a population comprising a phenotype comprising i) CD95+, CD45RO?, and CCR7+; and ii) CD62L+ or one or more of CD27+, CD28+, CD45RA+, and CD127+ to produce an isolated T memory stem cell population. Further embodiments of the invention provide related cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
Type:
Grant
Filed:
May 13, 2019
Date of Patent:
September 7, 2021
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Luca Gattinoni, Enrico Lugli, Mario Roederer, Nicholas P. Restifo
Abstract: The present invention pertains to extracellular vesicles (exosomes) that are produced by culturing tumor cells in the presence of various ligands or activators of innate immunity receptors and subsequently isolating and purifying the vesicles in the culture supernatant. The invention provides also pharmaceutical compositions comprising the inventive exosomes. The exosomes of the invention are provided as medicaments for example in the treatment of cancer diseases.
Abstract: The present invention relates to exosomes, loaded with biotherapeutic protein and/or peptide and methods of producing them and to the use of such exosomes for delivering protein and/or peptide in vivo, in particular the use of such exosomes in methods of therapy.
Type:
Grant
Filed:
December 7, 2012
Date of Patent:
August 31, 2021
Assignee:
Oxford University Innovation Limited
Inventors:
Matthew Wood, Samira Lakhal-Littleton, Samir El Andaloussi
Abstract: This disclosure is directed to methods for retrieving and using at least one lymphocyte. Additionally, cell receptor sequences identified with this strategy could be used for antibody development, TCR discovery, or appropriate therapeutics development or evaluation.
Abstract: The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more bone resorption marker levels, administering a sclerostin binding agent, then measuring the bone resorption marker levels. Also provided is a method of increasing bone mineral density; a method of ameliorating the effects of an osteoclast-related disorder; a method of treating a bone-related disorder by maintaining bone density; and a method of treating a bone-related disorder in a human suffering from or at risk of hypocalcemia or hypercalcemia, a human in which treatment with a parathyroid hormone or analog thereof is contraindicated, or a human in which treatment with a bisphosphonate is contraindicated.
Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
Type:
Grant
Filed:
December 2, 2020
Date of Patent:
August 10, 2021
Assignee:
Iovance Biotherapeutics, Inc.
Inventors:
Seth Wardell, James Bender, Michael T. Lotze